Kenneth Hoberman
Directeur des opérations chez STEMLINE THERAPEUTICS, INC.
Fortune : 5 M $ au 31/05/2024
Profil
Kenneth Hoberman is currently the Vice Chairman at Lirum Therapeutics, Inc., an Independent Director at TG Therapeutics, Inc., an Independent Director at Nuvectis Pharma, Inc., and the Chief Operating Officer at Stemline Therapeutics, Inc. Previously, he served as the Vice President-Corporate & Business Development at Keryx Biopharmaceuticals, Inc. from 2004 to 2012.
Mr. Hoberman completed his undergraduate degree at Boston University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
TG THERAPEUTICS, INC.
0,17% | 19/06/2024 | 264 935 ( 0,17% ) | 4 M $ | 31/05/2024 |
NUVECTIS PHARMA, INC.
0,56% | 13/06/2024 | 103 140 ( 0,56% ) | 698 258 $ | 31/05/2024 |
Postes actifs de Kenneth Hoberman
| Sociétés | Poste | Début |
|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Directeur des opérations | 01/01/2013 |
| TG THERAPEUTICS, INC. | Directeur/Membre du Conseil | 15/12/2014 |
| NUVECTIS PHARMA, INC. | Directeur/Membre du Conseil | 01/07/2021 |
Lirum Therapeutics, Inc.
 Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | Directeur/Membre du Conseil | 01/11/2021 |
Anciens postes connus de Kenneth Hoberman
| Sociétés | Poste | Fin |
|---|---|---|
| KERYX BIOPHARMACEUTICALS | Corporate Officer/Principal | 01/01/2012 |
Formation de Kenneth Hoberman
| Boston University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| TG THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
| Nuvectis Pharma, Inc. | |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | Health Technology |
